Furthermore, despite the administration of PEGylated G-CSF, a significant number of patients still develop neutropenia, suggesting a need for longer-lasting and more efficient versions of PEGylated G-CSF (Bartel et al., 1987; Lyman et al., 2010; Chan et al., 2011). The gene discussed is CSF3; the disease is neutropenia.